Related Experiment Videos
[Antithrombotic therapy for ischemic cerebrovascular accident]
1Unité neuro-vasculaire, service de neurologie, hôpital Sainte-Anne, Paris.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|December 26, 2002
Summary
For acute ischemic stroke patients ineligible for thrombolysis, aspirin is recommended, often with heparin for bed-ridden individuals. Secondary prevention for non-embolic stroke primarily uses antiplatelet drugs like aspirin or clopidogrel.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Context:
- Ischemic stroke management requires timely antithrombotic therapy for patients not receiving thrombolysis.
- Secondary prevention strategies differ based on stroke etiology (embolic vs. non-embolic) and patient risk factors.
Purpose:
- To outline current recommendations for antithrombotic therapy in acute ischemic stroke and secondary prevention.
- To differentiate treatment approaches for various stroke subtypes and risk profiles.
Summary:
- In acute ischemic stroke, aspirin (160-300 mg daily) is the primary treatment for non-thrombolysis candidates, with prophylactic heparin for immobile patients.
- Secondary prevention for non-embolic ischemic stroke favors antiplatelet agents (aspirin, clopidogrel, aspirin/dipyridamole).
- Oral anticoagulants are reserved for specific high-risk cases, including cardio-embolic stroke (e.g., atrial fibrillation) or clotting inhibitor deficiencies.
Impact:
- Provides evidence-based guidance for clinicians managing ischemic stroke patients.
- Aims to reduce stroke recurrence and associated thromboembolic complications.
- Highlights the importance of personalized antithrombotic strategies based on individual patient risk assessment.